Search Results
Sep 30, 2025, 12:00 ET Register Now for the 2025 National Disaster Resilience Conference: Shaping the Future of Disaster Preparedness and Recovery
Dr. Lawrence (Lars) Powell, Alabama Center for Risk and Insurance Research Director Steve Ruffner, KB Home President and Regional General Manager-Coastal The conference brings together nationally-recognized
More news about: Federal Alliance for Safe Homes (FLASH)
Sep 30, 2025, 08:07 ET EMQX Enterprise 6.0 Launches: Unifying MQTT with Message Queuing and Enterprise-Grade Multi-Tenancy
resilience for millions of concurrent connections. The new design is fully decoupled from broker metadata, reduces the disk footprint to approximately 1.5 KB per session, and supports sharded storage across the cluster for greater scalability.
More news about: EMQ Technologies
Sep 30, 2025, 08:00 ET Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout
a broad syndicate of investors, including Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, funds managed by abrdn Inc., KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners and Prebys Ventures Fund.
More news about: Crystalys Therapeutics
Sep 17, 2025, 07:00 ET BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–32.17. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate-to-severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled,
More news about: UCB
Sep 17, 2025, 07:00 ET BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–32.Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate-to-severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled,
More news about: UCB